ArticleAnnals of medicine and surgery (2012)2025
Pathophysiological role and clinical applications of HER-2 expression in meningiomas: a systematic review.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although typically benign, malignant meningiomas represent 1-3% of cases and exhibit poor survival rates. Environmental and genetic risk factors, including neurofibromatosis type 2 (NF2), obesity, and hormone-related exposure, influence meningioma development. Objective: This study investigated HER2 expression in meningiomas, exploring its potential as a therapeutic target and examining its role in tumor pathophysiology and grade progression. Methods: A systematic review was conducted through a comprehensive search of the PubMed database, and 12 studies meeting the inclusion criteria were selected. Studies focusing on HER-2/neu expression in meningiomas, published in English, and demonstrating methodological consistency were included in our study. Results: HER2 overexpression and gene amplification were identified in meningiomas, with higher expression correlating with tumor grade and recurrence rates. HER2-positive meningiomas exhibit enhanced invasion, migration, and proliferation via the HER2/PI3K/AKT pathway, implicating HER2 as a key player in tumor progression. Experimental studies have demonstrated that HER2 silencing reduces meningioma cell proliferation and angiogenesis by modulating vascular endothelial growth factor and CD34 expression. However, some studies have found no correlation between HER2 expression and meningioma characteristics. Conclusion: HER2 expression is closely associated with meningioma pathogenesis and grade. This highlights HER2 as a potential biomarker and therapeutic target, warranting further clinical trials to explore HER2-targeted therapies, such as trastuzumab, for aggressive and non-resectable meningiomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.